Genethon and Eukarÿs Unite to Cut Gene Therapy Costs with C3P3 Technology

Genethon, a frontrunner in the research and development of gene therapies for rare conditions, and Eukarÿs, a biotech firm innovating a breakthrough technology that greatly enhances biomanufacturing yields, announced the signing of a strategic alliance. The partnership seeks to lower the production expenses of gene therapy drugs by utilizing Eukarÿs’ exclusive C3P3 technology, an advanced messenger RNA (mRNA) expression system in mammalian cells.

Gene therapies provide significant hope for individuals affected by both rare and prevalent diseases. Nonetheless, the biomanufacturing of these treatments continues to be intricate and expensive, posing a significant barrier to their advancement and market entry. Enhancing production technologies and significantly boosting biomanufacturing yields are thus strategic objectives aimed at increasing patient access to these advanced therapies.

Eukarÿs has created a tailored enzyme, C3P3, that greatly boosts the production capabilities of cells utilized for biopharmaceutical synthesis by improving their mRNA synthesis functions. When paired with Genethon's knowledge and technologies, this novel method could greatly enhance the generation of AAV (Adeno-Associated Virus) vectors, which are among the primary vector types for delivering therapeutic genes to patients.

In this partnership, Genethon will offer its knowledge in AAV vector design and production, alongside its technologies and biomanufacturing capabilities, whereas Eukarÿs will supply its patented C3P3 technology and extensive expertise in mRNA synthesis.